Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects

被引：0
|
作者：
Song Mu
Zhiyu Tang
William Novotny
Manal Tawashi
Ta-Kai Li
Ying Ou
Srikumar Sahasranaman
机构：
[1] BeiGene USA,Clinical Pharmacology
[2] BeiGene USA,Clinical Development
[3] BeiGene USA,Clinical Operations
[4] BeiGene USA,Drug Safety and Pharmacovigilance
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 85卷
关键词：
Clinical pharmacology; Clinical trials; Drug–drug interactions; Oncology; Pharmacokinetics and drug metabolism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：391 / 399
页数：8
相关论文
共 50 条
  • [21] Population Pharmacokinetics of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib, in Healthy Volunteers and Patients with B-Cell Malignancies
    Edlund, Helena
    Andrew, Marilee
    Jin, Feng
    Patel, Priti
    Masson, Eric
    Slatter, J. Greg
    Aksenov, Sergey
    Al-Huniti, Nidal
    BLOOD, 2017, 130
  • [22] SAFETY, PHARMACOKINETICS AND PROOF-OF-MECHANISM OF AN ORAL BRUTON'S TYROSINE KINASE INHIBITOR HM71224 IN HEALTHY ADULT VOLUNTEERS
    Lee, J.
    Son, J.
    Sin, H. J.
    Woo, J.
    Hadi, S.
    Suh, K. H.
    Lee, Y. -M.
    Jang, S.
    Jung, J. -A.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 261 - 261
  • [23] The Effect of Rifampin On the Pharmacokinetics of Tivozanib, a Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor
    Cotreau, M.
    Subic, D.
    Massmanian, L.
    Strahs, A.
    Vargo, D.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 183 - 183
  • [24] The effect of Bruton ' s tyrosine kinase (BTK) inhibitor in the eosinophilic asthma model of mouse
    Choi, Yeji
    Kim, Seo-Hee
    Shin, Seung Jun
    Park, Hae-Sim
    Shin, Yoo Seob
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 132
  • [25] The effect of the CYP3A4 inhibitor, itraconazole, on the pharmacokinetics of ZD6474 in healthy subjects
    Smith, R
    Oliver, S
    Ghahramani, P
    Kennedy, S
    Gilmore, E
    Duvauchelle, T
    Hammett, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 222S - 222S
  • [26] POPULATION PHARMACOKINETIC MODEL OF EVOBRUTINIB, A BRUTON'S TYROSINE KINASE INHIBITOR - AN ANALYSIS OF TWO PHASE I CLINICAL TRIALS IN HEALTHY SUBJECTS.
    Papasouliotis, O.
    Mitchell, D.
    Dyroff, M.
    Girard, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S94 - S94
  • [27] First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects
    Neuman, Linda L.
    Ward, Renee
    Arnold, David
    Combs, Daniel L.
    Gruver, Deena
    Hill, Wendy
    Kunjom, Josue Mfopou
    Miller, Langdon L.
    Fox, Judith A.
    BLOOD, 2016, 128 (22)
  • [28] Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers
    Litzenburger, Tobias
    Steffgen, Juergen
    Benediktus, Ewald
    Mueller, Fabian
    Schultz, Armin
    Klein, Elliott
    Ramanujam, Meera
    Harcken, Christian
    Gupta, Alpana
    Wu, Jing
    Wiebe, Sabrina
    Li, Xiujiang
    Flack, Mary
    Padula, Steven J.
    Visvanathan, Sudha
    Huennemeyer, Andreas
    Hui, Jianan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (04) : 1824 - 1838
  • [29] Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis
    Angela W. Dymond
    Cathy Elks
    Paul Martin
    David J. Carlile
    Gabriella Mariani
    Susan Lovick
    Yifan Huang
    Ulrike Lorch
    Helen Brown
    Karen So
    European Journal of Clinical Pharmacology, 2017, 73 : 717 - 726
  • [30] Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis
    Dymond, Angela W.
    Elks, Cathy
    Martin, Paul
    Carlile, David J.
    Mariani, Gabriella
    Lovick, Susan
    Huang, Yifan
    Lorch, Ulrike
    Brown, Helen
    So, Karen
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (06) : 717 - 726
12345